Extended Data Table 2 CRS management in the overall R/R LBCL population (safety evaluable population)

From: Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial

  1. an represents the number of patients experiencing CRS at the specified grade. Note: some patients may have experienced CRS at more than one grade.
  2. bPercentages were calculated as the proportion of patients with CRS receiving the particular treatment for CRS. CRS was graded using ASTCT criteria.
Back to article page